First Automated Insulin System With Yearlong Sensor Launches

FDA-cleared twiist AID system pairs with Eversense 365 CGM to simplify Type 1 diabetes care

Topline

A first-of-its-kind insulin delivery system combining a yearlong implantable glucose sensor with automated insulin dosing will roll out in select U.S. markets in 2025, aiming to reduce the burden of Type 1 diabetes management.

Study Details

Sequel Med Tech and Senseonics have partnered to integrate the Eversense 365 continuous glucose monitor (CGM) an implantable sensor lasting one full year into the twiist Automated Insulin Delivery (AID) system. This system was cleared by the FDA in 2024 for people with Type 1 diabetes aged 6 and older, although the sensor is currently approved for those 18 and older.

Methodology

The twiist AID uses a subcutaneously implanted sensor, placed in the upper arm by a healthcare provider, with a wearable transmitter above it. The system incorporates real-time glucose data and predictive modeling through the twiist Loop algorithm (derived from the open-source Tidepool Loop) to modulate insulin delivery automatically. The twiist pump features a reusable base and a 300-unit insulin reservoir that requires replacement every three days.

Key Findings

• First device to combine a yearlong CGM with an AID pump

• Weekly calibration required, but daily fingersticks are eliminated

• Microdosed insulin is directly measured, improving dosing accuracy

• Real-time glucose prediction and automation through advanced algorithm

• Expected availability starting Q2 2025 in select U.S. markets

Implications for Practice

For adults with Type 1 diabetes, this innovation may dramatically reduce daily management tasks offering more freedom from routine fingersticks and manual insulin dosing.

For healthcare providers, it represents a new class of integrated diabetes technologies where long-term implantable sensors can be coupled with smart algorithms for tailored insulin therapy.

Pediatric providers may need to wait for broader age approval before recommending this system to younger patients.